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OBJECTIVE: Postal surveys only investigate HRQOL in
those who return questionnaires and also complete
enough information for analysis. Calculation of a single
index of HRQoL (EQ-5D index) is impossible where
data are missing. This study investigates completion of
EQ-5D and the factors associated with non-completion.
METHOD: A postal questionnaire was sent to 10,471
adults registered to two general practices in Manchester.
Non-responders received reminders after four and eight
weeks. Demographic information for non-responders was
obtained from general practitioner records. Indicators of
social deprivation were obtained from the Regional Health
Authority. EQ-5D rates 5 HRQOL domains on three lev-
els with overall health state marked on a visual analogue
scale (VAS) between 0 (worst) and 100 (best).
RESULTS: In total, 6838 (65.3%) questionnaires were
returned; 5954 (56.9%) were complete. The self-care do-
main was missed most often (5.6% of responders) fol-
lowed by anxiety/depression (4.4%), usual-activities (4.3%),
pain/discomfort (4.1%), and mobility (3.9%). There was
a significant difference in proportions between self-care
and anxiety/depression (4.4% vs 5.6%, difference 
0.121, 95% CI of difference 0.195 to 0.0481). Four
hundred thirty one people missed the VAS. Women were
more likely to miss domain questions (10.2% vs 7.7%,
chi2 12.67, p  .001) as were older respondents (mean
age 47.6 vs 57.7 t 12.16, p  .001). Missing data were
less common in those with further education or a degree
(10.3% vs 5.5% and 5.3% respectively, chi2 46.4, p 
0.001). Social deprivation was more common in those
who missed a question but this was not statistically sig-
nificant.
CONCLUSION: Low levels of non-completion were
found, although respondents were significantly less will-
ing to answer about self-care than about other domains,
possibly not wishing to appear dependent on others. The
importance of analyzing the degree of non-completion of
a questionnaire and possible associated factors should be
noted. Future work is needed to investigate HRQoL in
those who do not respond to or complete questionnaires.
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BASELINE ANEMIA AND RISK OF POOR 
RESPONSE TO CHEMOTHERAPY IN 
INTERMEDIATE GRADE NON-HODGKIN’S 
LYMPHOMA (IGNHL) PATIENTS
Lawless G, Gupta S, Tannous RE
Amgen, Inc, Thousand Oaks, CA, USA
Anemia at diagnosis (baseline) is a potential adverse
prognostic factor for no response to chemotherapy in ad-
dition to the standard risk factors.
OBJECTIVE: The purpose of this study was to identify
factors associated with baseline anemia and to determine
risk factors associated with no response to CHOP che-
motherapy in IGNHL patients.
METHODS: A historical case series sample of 591 pa-
tients diagnosed between 1993 and 1999, and treated in
12 practice sites with CHOP chemotherapy was used.
Baseline anemia was defined as a hemoglobin (Hb) value
12 g/dl at baseline. Multiple logistic regression was
used to determine factors associated with baseline anemia
and model its relationship with response [no response
(NR) versus partial response (PR) and complete response
(CR)].
RESULTS: Anemia was present in 193/546 (35.3%) pa-
tients. Baseline Hb values were not available for 45 pa-
tients. Multiple logistic regression showed that baseline
anemia was significantly associated with elevated LDH
(OR; 95%CI) (OR  2.74; 1.66–4.50), presence of B
symptoms (OR  2.16; 1.22–3.83), stage III-IV (OR 
1.81: 1.10–2.93), male gender (0.42: 0.25–0.69), and
large cell diffuse (OR  2.05; 1.19–3.54) or immuno-
blast (3.99; 1.78–9.02) histologic types. No significant
interactions existed between any of the variables included
in this model. Multiple logistic regression (predicting NR
versus CR/PR) showed that the presence of baseline anemia
(OR  2.29; 1.10–4.74) controlling for elevated LDH,
advanced Stage III-IV, and age greater than or equal to
60, was a significant risk factor for NR to CHOP chemo-
therapy.
CONCLUSION: The results support previous findings of
the high prevalence of, and risk factors associated with,
baseline anemia prior to CHOP chemotherapy. Baseline
anemia was a significant risk factor for NR to CHOP
chemotherapy, even after controlling for age, stage, and
LDH. We conclude that additional studies with a com-
prehensive set of known risk factors validating this rela-
tionship between baseline anemia and response to CHOP
chemotherapy are warranted.
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COST OF TREATMENT AND FOLLOW UP
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EVALUATION IN A COMPREHENSIVE
CANCER CENTRE
Lilliu H1, Morel J1, Brun C2, Berlie J3
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OBJECTIVE: Breast cancer is one of the major causes of
premature death for women. The management of its cost is
important for both the national health insurance and the in-
dividual health-care providers. The objective of this study
was to assess the global medical cost of breast cancer, from
diagnosis to follow up, in a French medical centre.
METHODS: Our evaluation was based on a retrospec-
tive cohort of 120 patients followed from January 1995
to February 2000 at Centre René Huguenin (Saint-
Cloud). Comprehensive treatment schemes and clinical
events were reported from patients’ medical files. De-
tailed medical consumptions and mean duration of staff
occupation were obtained primarily from direct observa-
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tion of the Centre’s activities, for each modality of pa-
tient follow-up and treatment (surgery, radiotherapy,
chemotherapy, consultations). Unit costs were obtained
from cost accounts of the Centre. Medical cost of breast
cancer was computed from the cancer-centre perspective,
by adding micro-costing and macro-costing components.
RESULTS: The mean medical cost per patient was €10
072 [95% CI 9 195; 10 948]. Costs per patient ranged
from €2 813 to €36 170. Median cost was of €8 860.
The initial treatment phase represented the most expen-
sive component, reaching €7 378 [7 040; 7 717] on aver-
age, which amounted to 73.3% of the global cost.
CONCLUSION: This study has provided an estimate of
the global cost of managing patients with breast cancer in
a French Comprehensive Cancer Centre (CLCC). Our es-
timates were consistent with those of the French national
database of costs per DRG. However, our approach has
the advantage of providing a cost per patient suitable for
cost-of-illness evaluations, rather than a cost per hospital
stay.
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USING LEVEL OF EVIDENCE CRITERIA 
IN THE EVALUATION OF 
PHARMACOECONOMIC RESULTS
Becker R1, Noe L1, Gore M2, Chen D1
1Ovation Research Group, Highland Park, IL; 2 Avalon Health 
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OBJECTIVE: To compare the pharmacoeconomic results
of a breast cancer treatment model for Japan using sev-
eral criteria, including level of evidence of the clinical
data.
METHODS: The Japanese Breast Cancer Treatment
Model (JBCTM) features treatment pathways for four
breast cancer stages. The model includes resources, costs,
and clinical outcomes for all treatments, and has the abil-
ity to estimate the cost-effectiveness of treatments in vari-
ous settings with consideration given to the level of evi-
dence. Guidelines from the American Society of Clinical
Oncology (ASCO) were used to stratify the clinical data
for drug treatments in the model. The ASCO levels of ev-
idence criteria are ranked from Level I, evidence from
studies showing the highest level of clinical results sup-
porting treatment usage, to Level V, those yielding the
weakest evidence for usage. For the JBCTM, the ASCO
definitions of Levels I and II were directly followed and
Levels III through V were combined into one level. The
model contains over 450 level-of-evidence references for
more than 60 drug treatments. An example of an evalua-
tion using the JBCTM is a cost-effectiveness analysis com-
paring one chemotherapy combination, CAF, to two other
regimens, CEF and CMF in advanced breast cancer.
RESULTS: Although the incremental cost-effectiveness
ratio for CAF compared to CEF is negative, indicating
CAF is a dominant strategy, the clinical evidence is only
Level II. In contrast, the incremental cost-effectiveness ra-
tio for CAF compared to CMF is positive, although rela-
tively low at 14,087¥ for each percentage increase in ob-
jective response, but the clinical evidence is Level I, the
highest possible.
CONCLUSIONS: Although the cost-effectiveness ratios
show that CAF is more cost-effective when compared to
CEF than when compared to CMF, the evidence level for
choosing CAF over CMF is higher. Decision-makers can
be more informed by considering both levels of evidence
and pharmacoeconomic data.
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COST-EFFECTIVENESS OF URATE OXIDASE
IN PREVENTION AND TREATMENT OF 
SEVERE HYPERURICEMIA AND 
TUMOUR LYSIS SYNDROME IN 
HAEMATOLOGIC MALIGNANCIES
Moeremans K1, Annemans LJ2
1HEDM, Meise, Belgium; 2Ghent University, HEDM, Meise, 
Belgium
OBJECTIVES: Hyperuricemia (HU) and tumour lysis
syndrome (TLS) are important complications leading to
morbidity and mortality in patients with haematologic
malignancies. The objective was to assess the cost-effec-
tiveness (CE), in terms of cost per life year saved (LYS),
of preventing or treating HU and TLS with recombinant
urate oxidase, rasburicase (FASTURTEC®).
METHODS: The current incidence and costs of HU and
TLS were studied in a multi-country chart review includ-
ing 788 adults and children treated for acute lymphoid or
myeloid leukaemia (ALL or AML) or non-Hodgkin lym-
phoma (NHL). Costs, expressed in Euro, were calculated
from the UK payer’s perspective. The average life expect-
ancy at the time of diagnosis was based on cancer sur-
vival rates and age at diagnosis reported in the literature.
Adult data were derived from the Eurocare study, child-
hood data from UK national statistics.
RESULTS: HU incidence was 18.9% and its average cost
was 1,679Euro (SE  519). TLS incidence was 5% and
its average cost was 11,202Euro (SE  2,147), and TLS-
related mortality was 0.8%. With 90% reduction of HU
and 100% reduction of TLS cases by rasburicase, the av-
erage CE of prevention in adults was 20,652Euro/LYS
for ALL, 83,824 Euro/LYS for AML and 31,667 Euro/
LYS for NHL. The high CE ratio in AML is explained by
its low life expectancy. In children the respective results
were only 379 Euro/LYS, 668 Euro/LYS, and 388 Euro/
LYS. Sensitivity analyses showed these results to be ro-
bust, especially in children. If applied only for treatment
of established HU/TLS, rasburicase is associated with
savings of 1,089 Euro in adults and 2,358 Euro in chil-
dren, becoming cost-saving as of a 65% and only 24%
reduction of TLS in adults and children respectively.
CONCLUSION: In prevention of HU/TLS, highly cost-
effective results can be obtained in children, and reason-
ably cost-effective results in adults with ALL. Both in
adults and children, treating HU with rasburicase would
be a cost saving intervention.
